



IMAGION BIOSYSTEMS LIMITED

APPENDIX 4E

FOR THE YEAR ENDED 31 DECEMBER 2022

1. Reporting period (“current period”): Year ended 31 December 2022  
 Previous corresponding period: Year ended 31 December 2021

2. Results for announcement to the market

Item		Movement	\$AUD
Revenue	up	7.5%	3,070,925
(Loss) from ordinary activities after tax attributable to members	down	62.8%	(9,807,208)
Net (loss) for the period attributable to members	down	65.4%	(9,283,642)

*Dividends*

There were no dividends paid, recommended or declared during the current period.

3. Consolidated Statement of Profit and Loss and Other Comprehensive Income

Refer to the attached Financial Statements together with notes for the year ended 31 December 2022.

4. Consolidated Statement of Financial Position

Refer to the attached Financial Statements together with notes for the year ended 31 December 2022.

5. Consolidated Statement of Cash Flows

Refer to the attached Financial Statements together with notes for the year ended 31 December 2022.

6. Consolidated Statement of Changes in Equity

Refer to the attached Financial Statements together with notes for the year ended 31 December 2022.

7. Dividends

*Current period:*

There were no dividends paid, recommended or declared during the period.

*Previous period:*

There were no dividends paid, recommended or declared during the previous financial period.

8. Dividend reinvestment plans

There are no dividend reinvestment plans operation.

9. Net tangible assets

	31 Dec 2022 \$AUD	31 Dec 2021 \$AUD
Net tangible asset backing per ordinary share	0.0042	0.0119

10. Details of entities over which control has been gained or lost

N/A

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Foreign Entities

Details of origin of Accounting Standards of foreign subsidiary:

Imagion Biosystems Limited owns 100% of Imagion Biosystems Inc. This company prepares their financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

14. Results for the period

Refer to the Letter from the Chair and Review of Operations contained within the attached Imagion Biosystems Limited Financial Report for the financial year ended 31 December 2022.

15. Status of Audit

The Financial Report has been audited.

16. Description of any likely audit dispute or qualification:

The Financial Report is not subject to dispute or qualification.